Autopsy report · NCT03121534

Ibrutinib, Nivolumab and Blinatumomab in Richter Transformation

“The study was closed for slow accrual”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months before it started.
• Ran for about 4 years 8 months before it stopped.
• 9 participants enrolled.
• Results were posted on the registry 1 year after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

M.D. Anderson Cancer Center

Sponsor type

University, hospital or other

Conditions

Hematopoietic/Lymphoid Cancer; Richter's Transformation

Interventions

Blinatumomab; Dexamethasone; Ibrutinib; Nivolumab

Participants

9

Sites

1

Countries

United States

Trials that died the same way

• Bone Marrow Transplant From Related Donor for Patients With High Risk Hemoglobinopathies
  “accrual was slow and sporadic so the study was closed” (93% match in meaning)
• S0002 - A Program to Quit Smoking With or Without Bupropion in Treating Patients With Stage I or II Non-Small Cell Lung Cancer Who Have Undergone Surgery
  “This study was closed early due to poor accrual” (87% match in meaning)
• Checkpoint Inhibitor and Radiation Therapy in Bulky, Node-Positive Bladder Cancer
  “Study was closed to low accrual.” (87% match in meaning)
• High Dose Rate Brachyablation of Primary Liver Lesions
  “Study was closed due to poor accrual” (85% match in meaning)
• Pre-operative Zoledronate in Triple Negative Breast Cancer
  “The study stopped prematurely due to the low accrual rate” (84% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.